Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients

Blood Pressure

Volumn 20, Issue SUPPL. 1, 2011, Pages 12-19

  Matsuno, Yasunari ^a   Minatoguchi, Shinya ^a   Fujiwara, Hisayoshi ^b  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

Author keywords

Amlodipine; candesartan; home blood pressure; left ventricular hypertrophy; QTc dispersion

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL ASSESSMENT; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGH RISK PATIENT; HOME CARE; HUMAN; HYPERTENSION; JAPANESE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QT DISPERSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; RISK; TETRAZOLES; TREATMENT OUTCOME;

EID: 79251477555     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2010.532339     Document Type: Article

References (25)

1. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effect of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension. 2008;51:393-398.
2. Ohkubo T, Imai Y, Tsuji I, Nagai K, Kato J, Kikuchi N, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: A population-based observation in Ohasama, Japan. Hypertension. 1998;16:971-975.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
4. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobiqio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
5. Lepeschkin E, Surawicz B. The measurement of the QT interval of the electrocardiogram. Circulation. 1952;6:378-388.
6. Higham PD, Campbell EWF. QT dispersion. Br Heart J. 1994;71:508-510.
7. Day CP, McComb JM, Campbell EWF. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals. Br Heart J. 1990;63:342-344.
8. Taran LM, Szilagyi N. The duration of the electrical systole (Q-T) in acute rheumatic carditis in children. Am Heart J. 1947;33:14-26.
9. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, et al. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: Rationale, design, and methods. Hypertens Res. 2003;26:979-990.
10. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.
11. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115:41-46.
12. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;7:450-458.
13. Barr CS, Naas AA, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet. 1994;343:327-329.
14. Sporton SC, Taggart P, Sutton PM, Walker JM, Hardman SM. Acute ischaemia: A dynamic influence on QT dispersion. Lancet. 1997;349:306-309.
15. Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsades de pointes. Disparate effects of class 1a antiarrhythmic drugs and amiodarone. Circulation. 1992;86:945-948.
16. de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. QTc dispersion predicts cardiac mortality in elderly: The Rotterdam Study. Circulation. 1998;97:467-472.
17. Lim PO, Nys M, Naas AAO, Struthers AD, Osbakken M, MacDonald TM. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension. 1999;33:713-718.
18. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of action of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol. 2002;90:1107-1112.
19. Crozier IG, Richards AM, Ikram H, Nicholls MG. The renin - angiotensin system, ACE inhibitors, and cardiac structure. In: Robertson JIS, editor. The renin - angiotensin system. New York: Gower Medical Publishing; 1993. p 1-94.
20. Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV, et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J. 1998;136:765-768.
21. Bednarz B, Chamiec T, Ceremuzynski L. Antioxidant vitamins decrease exercise-induced QT dispersion after myocardial infarction. Kardiol Pol. 2003;58:375-379.
22. Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, et al. The reduction of QTc dispersion by angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension. Hypertens Res. 2007;30:307-313.
23. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005;16:3631-3641.
24. Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T, Kawasaki H, et al. Candesartan decreases carotid intimamedia thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res. 2008;31:271-279.
25. Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, et al. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: Rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex). Contemp Clin Trials. 2009;30:97-101.